Imunon, Inc. ((IMNN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Imunon, Inc. has completed a Phase 1/2 study titled Phase 1/2, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of a DNA Vaccine, IMNN-101, Administered as a Single Dose in Healthy Adults Previously Vaccinated Against SARS-CoV-2. The study aimed to assess the safety and immune response of the IMNN-101 vaccine, which is significant in advancing COVID-19 vaccination strategies.
Intervention/Treatment: The study tested IMNN-101, a DNA vaccine designed to target the SARS-CoV-2 Omicron XBB.1.5 spike antigen. It is administered as a single intramuscular dose and formulated with Crown poloxamer and AlPO4 as adjuvants.
Study Design: This interventional study followed a single-group model with no masking, focusing on prevention. Participants received varying doses of IMNN-101, and the study proceeded in a staged manner to ensure safety.
Study Timeline: The study began on June 4, 2024, and was last updated on July 22, 2025. These dates are crucial as they mark the study’s progression and recent updates.
Market Implications: The completion of this study could positively impact Imunon, Inc.’s stock performance by enhancing investor confidence in its vaccine pipeline. As the COVID-19 vaccine market remains competitive, successful results could position Imunon favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.